Prostate cancer therapies have shown significant advances during the past decade, with multiple new therapies being introduced for patients with advanced disease. Now, the early results of a clinical trial published in the New England Journal of Medicine (NEJM) reveals for the first time that therapies based on tumor genetics – specifically DNA repair defects...
by CORDIS The European Bank for induced Pluripotent Stem Cells (EBiSC) and CHDI Foundation have collaborated with Censo Biotechnologies to generate a cohort of 45 iPSC lines derived from Huntington’s disease gene-expansion carriers and associated controls. These new lines will be used to further investigate the mechanisms of HD progression and for the development of...
